ArticleJournal of clinical medicine2021

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis.

Shin-Seok Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.